Incremental net benefit of extending human papillomavirus vaccine to boys in oropharyngeal cancer burden: Meta-analysis of cost-effectiveness studies

被引:0
作者
Pratama, Adikara Pagan [1 ,2 ]
Chen, Su-Feng [3 ]
Liao, Shih-Chieh [4 ]
Su, Wei-Chia [3 ,5 ]
Yu, Jian-Hong [3 ,6 ]
机构
[1] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung, Taiwan
[2] Univ Airlangga, Fac Med, Dept Publ Hlth & Prevent Med, Surabaya, Indonesia
[3] China Med Univ, Coll Dent, Sch Dent, 91 Xueshi Rd, Taichung 40402, Taiwan
[4] China Med Univ, Sch Med, Dept Radiol, Taichung, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Dept Dent, Div Oral & Maxillofacial Surg, 100,Tzyou 1st Rd, Kaohsiung 80756, Taiwan
[6] China Med Univ Hosp, Dept Dent, Orthodont, Taichung, Taiwan
关键词
Meta-analysis; Oropharyngeal cancer; Incremental cost- effectiveness ratio; Incremental net benefit; HPV VACCINATION; UNITED-STATES; HEALTH; PREVENTION; IMPACT;
D O I
10.1016/j.jds.2024.05.032
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background/purpose: The incidence of human papillomavirus (HPV)-r elated oropharyngeal cancer (OPC) is increasing worldwide. HPV vaccines have shown efficacy in preventing diseases in both males and females. Therefore, there is a need to develop costeffective strategies for HPV vaccines to prevent HPV-related OPC. This meta-analysis aimed to evaluate cost-effectiveness using the global mean of incremental cost-effectiveness ratios compared to the willingness-to-pay threshold and incremental net benefits (INBs) of HPV vaccination strategies between boys' extension vaccine and girls only. These recommendations will be useful for countries that have not implemented universal HPV vaccines in national programs, such as Taiwan. Materials and methods: Studies evaluating the cost-effectiveness of HPV vaccination strategies in the prevention of OPC that included both sexes versus girls only were identified through the Cochrane Library, EMBASE, PubMed, ScienceDirect, and Web of Science databases on February 05, 2024, and a meta-analysis of pooled INBs was performed using a random effects model. The outcome was an effective measurement of the OPC burden. The results are represented in USD (2024). Results: Fifteen model analyses were included. All the studies were conducted in high-income countries. The global mean of incremental cost-effectiveness ratio was $39,553 (95% CI, $27,008-66,641) per quality-adjusted life years gained, which was below the global mean of the willingness-to-pay threshold of $65,473 (95% CI, $52,138-83,755). Pooled INBs of $9370 (95% CI, $5046-13,695; P < 0.001) favored the extended HPV in boys. Conclusion: HPV vaccination strategies that include boys are cost-effective compared to those with girls only in preventing OPC burden. By implementing a universal HPV vaccination program, countries can receive $9370 in additional monetary benefits per patient. Given its relevance to high-income countries, this study offers key insights that can aid policymakers in Taiwan.
引用
收藏
页码:2045 / 2056
页数:12
相关论文
共 52 条
  • [41] Human Papillomavirus-Attributable Cancers - United States, 2012-2016
    Senkomago, Virginia
    Henley, S. Jane
    Thomas, Cheryll C.
    Mix, Jacqueline M.
    Markowitz, Lauri E.
    Saraiya, Mona
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2019, 68 (33): : 724 - 728
  • [42] Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands
    Simons, Joost J. M.
    Vida, Nora
    Westra, Tjalke A.
    Postma, Maarten J.
    [J]. VACCINE, 2020, 38 (30) : 4687 - 4694
  • [43] Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination
    Siok Shen Ng
    Hutubessy, Raymond
    Chaiyakunapruk, Nathorn
    [J]. VACCINE, 2018, 36 (19) : 2529 - 2544
  • [44] Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis
    Tejada, Romina A.
    Malagon, Talia
    Franco, Eduardo L.
    [J]. VACCINE, 2022, 40 (19) : 2667 - 2678
  • [45] Adverse events from HPV vaccination in Taiwan
    Tsai, Sz-An
    Lu, Chun-Yi
    Chen, Tzu-, I
    Huang, Shih-Pei
    Chen, Yong-Chen
    [J]. VACCINE, 2023, 41 (49) : 7444 - 7449
  • [46] National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects
    Tsu, Vivien D.
    LaMontagne, D. Scott
    Atuhebwe, Phionah
    Bloem, Paul N.
    Ndiaye, Cathy
    [J]. PREVENTIVE MEDICINE, 2021, 144
  • [47] Wang CP, 2022, BMC CANCER, V22, DOI [10.1186/s12885-022-09407-5, 10.1186/s12890-022-01985-1]
  • [48] Measuring the statistical validity of summary meta-analysis and meta-regression results for use in clinical practice
    Willis, Brian H.
    Riley, Richard D.
    [J]. STATISTICS IN MEDICINE, 2017, 36 (21) : 3283 - 3301
  • [49] Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour
    Wolff, Ellen
    Elfstrom, K. Miriam
    Cange, Hedda Haugen
    Larsson, Sofie
    Englund, Helene
    Sparen, Par
    Roth, Adam
    [J]. VACCINE, 2018, 36 (34) : 5160 - 5165
  • [50] Wu Ying-Hui, 2023, Int J Environ Res Public Health, V20, DOI 10.3390/ijerph20043717